Advisors Asset Management Inc. cut its stake in shares of Qiagen NV (NASDAQ:QGEN) by 69.4% during the second quarter, Holdings Channel reports. The institutional investor owned 7,916 shares of the company’s stock after selling 17,951 shares during the period. Advisors Asset Management Inc.’s holdings in Qiagen NV were worth $173,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Stephens Inc. AR raised its position in Qiagen NV by 14.5% in the second quarter. Stephens Inc. AR now owns 8,255 shares of the company’s stock valued at $180,000 after buying an additional 1,043 shares in the last quarter. Fuller & Thaler Asset Management Inc. purchased a new position in Qiagen NV during the second quarter valued at approximately $116,000. Manning & Napier Advisors LLC raised its position in Qiagen NV by 31.7% in the second quarter. Manning & Napier Advisors LLC now owns 6,111,364 shares of the company’s stock valued at $133,287,000 after buying an additional 1,470,315 shares in the last quarter. Aviva PLC raised its position in Qiagen NV by 37.8% in the second quarter. Aviva PLC now owns 195,350 shares of the company’s stock valued at $4,230,000 after buying an additional 53,570 shares in the last quarter. Finally, Timber Hill LLC purchased a new position in Qiagen NV during the second quarter valued at approximately $219,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.
Qiagen NV (NASDAQ:QGEN) traded down 0.51% on Thursday, reaching $27.41. The company had a trading volume of 276,805 shares. Qiagen NV has a 1-year low of $19.94 and a 1-year high of $28.04. The stock has a market capitalization of $6.41 billion, a P/E ratio of 54.82 and a beta of 0.83. The stock’s 50 day moving average is $26.79 and its 200-day moving average is $23.75.
Qiagen NV (NASDAQ:QGEN) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Qiagen NV had a return on equity of 9.21% and a net margin of 9.13%. The firm earned $334.40 million during the quarter, compared to analysts’ expectations of $326.73 million. During the same period last year, the business posted $0.26 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. On average, equities analysts predict that Qiagen NV will post $1.09 EPS for the current fiscal year.
Several research firms have commented on QGEN. DZ Bank AG reissued a “buy” rating on shares of Qiagen NV in a report on Monday, September 19th. Commerzbank AG reaffirmed a “buy” rating on shares of Qiagen NV in a report on Friday, September 16th. Zacks Investment Research raised shares of Qiagen NV from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Wednesday, September 14th. Morgan Stanley set a $30.00 price target on shares of Qiagen NV and gave the company a “buy” rating in a report on Sunday, September 11th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Qiagen NV in a report on Thursday, August 4th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $25.36.
About Qiagen NV
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NASDAQ:QGEN).
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.